Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Immutep Limited (NASDAQ: IMMP).

Full DD Report for IMMP

You must become a subscriber to view this report.


Recent News from (NASDAQ: IMMP)

Immutep to Present Interim Results from TACTI-mel Clinical Trial in Global Webcast
Chief Medical Officer Dr. Frederic Triebel to Present at the 3rd Annual Advances in Immuno-Oncology Congress SYDNEY, Australia, May 17, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM) (NASDAQ:IMMP) ("Immutep“ or “the Company“), a biotechnology company develop...
Source: GlobeNewswire
Date: May, 17 2018 08:00
Immutep to Present at 2018 ASCO Annual Meeting
SYDNEY, Australia, May 04, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM) (NASDAQ:IMMP) (Immutep or the Company) today announced that it will present posters during the 2018 American Society for Clinical Oncology (ASCO) Annual Meeting, being held 1-5, June 2018 in Chicago, Illinois. ...
Source: GlobeNewswire
Date: May, 04 2018 04:00
Investor Expectations to Drive Momentum within Criteo S.A, Prima BioMed, CoStar Group, DBV Technologies S.A, Hollysys Automation Technologies, and China Biologic Products - Discovering Underlying Factors of Influence
NEW YORK, April 13, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Criteo S.A. (NASDAQ:CRTO), Immutep Limited (NASDAQ:IMMP), CoStar Group, ...
Source: GlobeNewswire
Date: April, 13 2018 07:45
Immutep Completes A$6.31 Million Share Purchase Plan; Raises Total of A$13.16 Million
SYDNEY, Australia, April 12, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM) (NASDAQ:IMMP) (“ Immutep ” or the “ Company ”) advises that its Share Purchase Plan (“SPP”) closed as planned on 6 April 2018. The Company received applications from eli...
Source: GlobeNewswire
Date: April, 12 2018 21:24
Edison Issues Update on Immutep (IMMP)
LONDON, UK / ACCESSWIRE / March 29, 2018 / Immutep Limited (NASDAQ: IMMP) (ASX: IMM) has entered a clinical trial collaboration and supply agreement with Merck & Co (MSD) for a Phase II study to evaluate eftilagimod alpha (IMP321) plus Keytruda in lung, head and neck and ovarian cancers....
Source: ACCESSWIRE IA
Date: March, 29 2018 10:30
Immutep (IMMP) Presents At 3rd Annual Immuno-Oncology Summit Europe - Slideshow
The following slide deck was published by Immutep Limited ADR in conjunction with this Read more ...
Source: SeekingAlpha
Date: March, 26 2018 13:05
Updated TACTI-mel Data Presented at the Cambridge Healthtech Institute's Immuno-Oncology Summit
SYDNEY, Australia, March 22, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM) (NASDAQ:IMMP) (“Immutep” or the “Company”) is pleased to announce the presentation of updated data from its TACTI-mel Phase I clinical trial in Australia investigating the use of efti...
Source: GlobeNewswire
Date: March, 22 2018 19:45
Immutep Commences Patient Dosing in Additional TACTI-mel Cohort
SYDNEY, Australia, March 21, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM) (NASDAQ:IMMP) (“Immutep” or the “Company”) has announced the initiation of patient dosing in the new cohort of the TACTI-mel ( T wo ACT ive I mmunotherapies in melanoma) Phase 1 cli...
Source: GlobeNewswire
Date: March, 21 2018 18:28
New Research Coverage Highlights Amarin, Corbus Pharmaceuticals, Green Brick Partners, Immutep, Texas Capital Bancshares, and G1 THERAPEUTICS - Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, March 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Amarin Corporation PLC (NASDAQ:AMRN), Corbus Pharmaceuticals Holdings, I...
Source: GlobeNewswire
Date: March, 16 2018 08:10
Midday Gainers / Losers (3/12/2018)
Gainers: BXC +83% . RKDA +51% . MARA +31% . OCLR +27% . NETE +23% . UCBA +23% . CPAH +18% . IMMP +17% . JNP +17% . More news on: BlueLinx Holdings, Inc., Arcadia Biosciences, Marathon Patent Group, Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: March, 12 2018 12:45

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-172.192.132.22242.1346,305

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-2468,86799,87168.9560Short
2018-05-2325,08653,14447.2038Short
2018-05-227,22920,74134.8537Cover
2018-05-215,68916,49234.4955Cover
2018-05-182,9064,16069.8558Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on IMMP.


About Immutep Limited (NASDAQ: IMMP)

Logo for Immutep Limited (NASDAQ: IMMP)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: IMMP)

      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 07 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 26 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 13 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 13 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 04 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 23 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 20 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 16 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 16 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 13 2018

       

       


      Daily Technical Chart for (NASDAQ: IMMP)

      Daily Technical Chart for (NASDAQ: IMMP)


      Stay tuned for daily updates and more on (NASDAQ: IMMP)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: IMMP)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      The Subway Trader
      @TheSubwayTrader

       

       


      Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in IMMP is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of IMMP and does not buy, sell, or trade any shares of IMMP. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/